FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.
Also in This 8-page Issue: NCI Seeks $6.17 Billion in “Bypass” Budget Request, But Faces Shortfall In Its Actual Budget.
NCI Names 15 to Director’s Consumer Liaison Group.
SAIC-Frederick Makes Awards To Proteomics Research Teams.
Latest State Cancer Statistics Released.
Smokers May Get Cessation Help From Medicare.
Funding Opportunities Listed.
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Hegseth offers soldiers testosterone and FDA loosens safety warnings. Is the science there?
- FDA’s OCE publishes three final guidances to increase clinical trial enrollment
